Zynex Inc., a medical technology company, announced today it has been granted license approval from the state of Arkansas for its compound pharmacy business Pharmazy.
This license approval brings the total states in which the company is licensed to provide compound pharmacy services to 43 plus the District of Columbia.
“We are pleased with the expansion of our reach across the United States for our compound pharmacy with the addition of Arkansas, our 44th license. We continue to work towards licensing in all 50 states,” Zynex CEO Thomas Sandgaard said.
Zynex was founded in 1996 and markets and sells its own design of electrotherapy medical devices for pain management and rehabilitation. The company specializes in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics and compound pharmacy,
Zynex’s product lines are fully developed, FDA-cleared and commercially sold worldwide. Zynex also operates a non-sterile compound pharmacy providing topical and transdermal pain creams and is developing a new blood volume monitor for use in hospitals and surgery centers.
Pharmazy Inc. maintains the intimacy of a neighborhood pharmacy focused on personalized health care. The Pharmacy provides the personal care expected but not always received at many pharmacies today.